In a competitive field, executives express confidence they will win the ‘foot race’ By Allison DeAngelis May 14, 2026 Biotech Startups and Venture Capital Reporter CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials. Up until last year, CREATE was known as […]

Acquisition will Accelerate Global Expansion of Company’s Breakthrough Edison® Histotripsy Platform and Non-Invasive Tumor Therapy MINNEAPOLIS–(BUSINESS WIRE)–HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced a management-led majority stake acquisition by a syndicate of globally recognized private and public investors, including K5 Global, Bezos Expeditions, Wellington Management and other […]

Atsena Therapeutics’ $150 million fundraise is a light of hope for the gene therapy field, which has suffered enormously in recent months. Atsena Therapeutics has raised $150 million in an oversubscribed series C financing, with hopes that the funds can carry the biotech’s gene therapy designed to reverse or prevent blindness through a potential market […]

Oversubscribed financing led by strategic investor, with participation from new and existing investors MINNEAPOLIS, June 25, 2024 /PRNewswire/ — Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes, announced it has closed an oversubscribed Series C financing totaling $88 million. The new capital will be used to complete the pivotal ReCET […]

CHICAGO, Dec. 8, 2022 /PRNewswire/ — Cardiosense, Inc., a Chicago-based digital health company leveraging artificial intelligence and multi-sensor devices to enable early detection of cardiovascular disease, announced today that it has raised $15.1 million in Series A funding, co-led by Broadview Ventures and Hatteras Venture Partners, with participation from Laerdal Million Lives Fund, OSF Ventures, UnityPoint Health Ventures, and Portal Innovations. […]

Acquisition Enables Company to Provide More High-Value, Patient-Centered Services Through Its Network of More Than 1,000 Independent Primary Care Practices and Health Centers   Bethesda, Md. — January 11, 2022 — Aledade, the leading primary care enablement company, announced today that it has acquired Iris Healthcare, the best-in-class provider of Advance Care Planning (ACP) solutions for tens of […]

First Indication for Lead TREM2 Agonist Program Announced as Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Financing Led by Vida Ventures; Stefan Vitorovic, Co-founder and Managing Director, to Join Board of Directors Cambridge, Mass., August 18, 2021—Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, today […]

CINCINNATI, June 1, 2021 /PRNewswire/ — Cincinnati-based Standard Bariatrics, Inc., has developed the Titan SGS™, a first-of-its-kind design that offers surgeons performing sleeve gastrectomy, the top bariatric surgical procedure for obesity disease, the industry’s longest continuous staple cutline of 23 centimeters.1 Standard Bariatrics®, an emerging leader in the bariatric surgery medical device field, today announced the completion of […]

Exclusive license for Asia (ex-Japan), Australia and New Zealand; Parties plan to conduct combination studies with BeiGene’s anti-PD-1 antibody tislelizumab BOSTON & CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–Feb. 17, 2021– Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel antagonist antibodies for cancer and other diseases, and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that they have entered into an option and license agreement […]

Therapy currently being evaluated in Phase I/II clinical study Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness DURHAM, N.C., July 29, 2020 (GLOBE NEWSWIRE) — Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or […]

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–AtaCor Medical, Inc. announced today that is has completed a $25M Series B financing. The financing syndicate, led by a corporate partner, includes existing investors Broadview Ventures and aMoon Fund as well as new investors Hatteras Venture Partners, Catalyst Health Ventures (CHV) and Longview Ventures, a Broadview affiliate. The investment supports efforts to […]

REDWOOD CITY, Calif., Feb. 28, 2020 – Graybug Vision, Inc., a biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic nerve, today presented preclinical study results for GB-401, a novel injectable depot formulation of a proprietary beta-adrenergic antagonist prodrug, as a potential sustained-delivery treatment of up to six months […]

BioSpace.com selected Qpex to be among Top Life Science Companies to Watch in 2020. BioSpace.com is one of the most comprehensive Life Science industry news and information sources in the world and you can read more about the other companies recognized here: https://www.biospace.com/article/top-21-life-science-startups-to-watch-in-2020/?s=106  Qpex was ranked in the top 10 of the 21 companies recognized. […]

Leading Patient Experience Platform Advances Company’s Market Position November 13, 2019 08:00 AM Eastern Standard Time IRVINE, Calif.–(BUSINESS WIRE)–NextGen Healthcare, Inc. (NASDAQ:NXGN) (“NextGen Healthcare” or “the Company”), a leading provider of ambulatory-focused technology solutions, today announced an agreement to acquire Medfusion, Inc. (“Medfusion”) a patient experience platform leader. The proposed acquisition is expected to close in […]

Jennifer Huber October 11, 2019 When Jason Melehani, MD, PhD, grew up in a small town in the Sierra Nevada foothills, he didn’t know any scientists or doctors. That all changed when he went to college at the University of California, Los Angeles and discovered the world of research. Now, Melehani is a resident in […]

Redwood City, CA – August 20, 2019 – Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), today announced the securing of an $80 million Series C […]

SAN DIEGO, June 13, 2019 /PRNewswire/ — Qpex Biopharma today announced that preclinical data on its investigational beta-lactamase inhibitor QPX7728 will be featured in several presentations at the 2019 ASM Microbe Meeting to be held June 20-24 in San Francisco, CA. “We are pleased to be making the first public presentations on our next generation beta-lactamase inhibitor QPX7728 that exceeds the […]

SAN DIEGO, April 30, 2019 /PRNewswire/ — Qpex Biopharma today announced the closing of a license agreement from Monash University providing Qpex a portfolio of next-generation polymyxin antimicrobials focused against highly drug-resistant gram-negative pathogens. The exclusive license includes worldwide rights to develop and commercialize polymyxin antimicrobials in multiple territories.   The polymyxin class of antibiotics, including the […]

PB2452 achieved immediate and sustained reversal of ticagrelor antiplatelet effects Results support continued development of PB2452 as ticagrelor reversal agent MALVERN, Penn. and SAN DIEGO, March 17, 2019 (GLOBE NEWSWIRE) —  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that […]

Non-Invasive Surgical Robotics Company with “Pure Sci-Fi” Technology Joins The Observer’s List of Top Firms ANN ARBOR, Mich., Jan. 7, 2019 /PRNewswire/ — HistoSonics, a privately-held company developing a non-invasive robotics platform for treating disease, has been named by The Observer as one of the nation’s hottest medical technology companies. The list, released today, highlights an array of digital health […]

ALPHARETTA, Ga., Oct. 25, 2018 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Thomas A. Ciulla, M.D., M.B.A. to the position of Chief Medical Officer. A board certified ophthalmologist and retinal specialist, Dr. […]

March 20, 2018 — AUSTIN, TX (BUSINESS WIRE) — Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, announced today $16 million in Series B funding led by Hatteras Venture Partners and Noro-Moseley Partners with participation from FS Healthcare LLC, Excelerate Health Ventures and all existing Series A investors including Shumway Capital.

January 16, 2018 — BOSTON — Press Ganey today announced the acquisition of Bivarus, which offers real-time patient and caregiver insights through a patented, dynamic consumer feedback platform. The addition of Bivarus’s capabilities complements Press Ganey’s comprehensive suite of solutions designed to help clients improve the overall safety, quality and experience of care for consumers and achieve the goal of zero harm.

Sept. 18, 2017 — CAMBRIDGE, MA — Rodin Therapeutics, a biotechnology company discovering and developing novel therapeutics to boost synaptic resilience, announced today significant progress in advancing the company’s strategic vision, including the completion of a $27 million financing round, and the addition of three new members to its Board of Directors.

May 16, 2017 (GLOBE NEWSWIRE) — RESEARCH TRIANGLE PARK, N.C. — G1 Therapeutics, Inc., a clinical-stage oncology company, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $105,000,000.

RESEARCH TRIANGLE PARK, N.C., January 6, 2017, – Viamet Pharmaceuticals, Inc. today reported positive results from RENOVATE (REstoring Nail; an Oral VT-1161 Tablet Evaluation), its Phase 2b clinical trial of VT-1161 in onychomycosis of the large toenail. Onychomycosis is a chronic fungal infection involving the nail, nail bed, and surrounding tissues. VT-1161, the company’s lead product candidate, is a highly potent and selective orally available inhibitor of fungal CYP51.

Ann Arbor, MI – September 13, 2016 – HistoSonics, Inc. (https://www.histosonics.com ) (the “Company”) announced today that noted radiologist and tumor ablation expert Fred Lee, Jr., MD, has joined the Company as Senior Medical Advisor and Board member to advance HistoSonics’ innovative tissue-destruction technology in liver cancer and other solid tumor applications.

ALPHARETTA, Ga., June 01, 2016 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the pricing of its initial public offering of 7,200,000 shares of its common stock at a public offering price of .00 per share. 

Alpharetta, GA (April 26, 2016) – Clearside Biomedical, Inc. today announced that its Phase 2 clinical trial evaluating concomitant administration of suprachoroidal ZUPRATA™, Clearside’s proprietary form of triamcinolone acetonide, together with intravitreal aflibercept (EYLEA®), for the treatment of macular edema associated with retinal vein occlusion (RVO), achieved its primary endpoint. 

ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced positive results from the company’s Phase 2 clinical trial of CLS-TA, Clearside’s proprietary form of triamcinolone acetonide, using suprachoroidal space (SCS™) drug administration for the treatment of macular edema associated with non-infectious uveitis.

It’s been more than a decade in the making, but Qvella is close to the holy grail of diagnostics–a compact, inexpensive pathogen analyzer that identifies the precise culprit in only 30 minutes. The idea is to enable better infection treatment faster as well as to minimize the overuse of antibiotics, which leads to the development of resistance.

SAN FRANCISCO, June 25, 2015 — Wildflower Health, maker of mobile maternity program Due Date Plus (www.wildflowerhealth.com/programs), today announced a $5 million investment in the company to facilitate its strategic expansion. New investors Easton Capital and Hatteras Venture Partners led the funding round with participation by existing investors Cambia Health Solutions and HealthTechCapital.

Alpharetta, GA and Emeryville, CA (May 4, 2015) – Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, and Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd., today announced the expansion of their research collaboration to include the field of glaucoma.

Malvern, PA, March 12, 2015 — PhaseBio Pharmaceuticals, Inc., a leading company in the field of biopolymer-based drugs and focused on developing treatments for metabolic and specialty cardiopulmonary disorders, today announced that it has closed a $40 million Series C financing round led by AstraZeneca.

RESEARCH TRIANGLE PARK, N.C., Feb. 5, 2015 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in oncology, today announced the completion of a $33 million Series B financing round. Lead investors Eshelman Ventures and RA Capital Management were joined by new investors Lumira Capital and Boxer Capital of Tavistock Life Sciences, as well as the company’s existing investors Hatteras Venture Partners, MedImmune Ventures, and Mountain Group Capital.

RESEARCH PARK TRIANGLE, NC, September 10, 2014 – G1 Therapeutics, Inc., a privately held, clinical-stage pharmaceutical company, today announced the initiation of a Phase 1 clinical trial of G1T28-1, a highly potent and selective CDK4/6 inhibitor with broad potential in multiple oncology indications.

Research Triangle Park, NC, May 20, 2014 – G1 Therapeutics, Inc., a privately held pharmaceutical company that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications, today announced the appointment of Mark Velleca, M.D., Ph.D. as chief executive officer, effective immediately.

Chapel Hill, NC, January 7, 2013– G1 Therapeutics, Inc. today announced that it has named Seth Rudnick, M.D. as executive chairman of its board of directors, effective immediately. Dr. Rudnick has been serving as the chair of G1’s Scientific Advisory Board for the past year and will continue in this role with the company.

Using the genetic properties of tumors to classify them more specifically and determine whether they may respond to anti-angiogenic drugs has netted a two-year-old diagnostics firm a .5 million round.

STONY BROOK, NY – (MARKETWIRE via COMTEX) – Coferon Inc., a privately held, New York-based biotechnology company, today announced that it has closed on a $12 million Series B financing round led by a trio of new venture investors: Hatteras Venture Partners of Durham, N.C.; MedImmune Ventures of Gaithersburg, MD (the corporate venture arm of AstraZeneca Ltd); and Ascent Biomedical Ventures of New York, N.Y.

MORRISVILLE, N.C. (Business Wire) – Clinipace Worldwide, a global digital clinical research organization (dCRO) that has pioneered technology-amplified contract research services, announced today it has closed a $15M Series C round of funding led by Morgan Stanley Expansion Capital of San Francisco, CA. Existing investors, including Hatteras Venture Partners of Durham, NC, and Brook Private Equity Advisors of Boston, MA, also participated in this most recent round of funding.

Asthmatx offers first FDA-approved non-drug procedure for the treatment of severe asthma NATICK, Mass. and SUNNYVALE, Calif., (PRNewswire-FirstCall) – Boston Scientific Corporation (NYSE: BSX) today announced the signing of a definitive merger agreement, under which Boston Scientific will acquire Asthmatx, Inc., a privately held company in Sunnyvale, California. Asthmatx designs, manufactures and markets a less-invasive, catheter-based […]

Morrisville, NC – Clinipace, global technology-driven clinical research organization (CRO), announced today that is has closed its acquisition of Worldwide Clinical Research, Inc. (WWCR), a Midwest-based CRO specializing in the management of clinical studies for biotechnology and pharmaceutical companies. With the acquisition, Clinipace has changed its name to Clinipace Worldwide, Inc.

Research Triangle Park, NC – Viamet Pharmaceuticals, Inc. announced today that it has secured $18 million in a Series B financing to accelerate the development of its novel metalloenzyme inhibitors and to advance its Metallophile™ Technology platform. The proprietary Metallophile™ Technology is based on Viamet’s world-class expertise in bioinorganic chemistry and metalloenzymes and allows Viamet to rapidly and cost-effectively generate “best-in-class”, novel compounds by optimizing the metal-binding component of existing metalloenzyme inhibitors. The investment was led by the Novartis Option Fund and Lilly Ventures and also included Viamet’s existing investors Intersouth Partners, Hatteras Venture Partners, Lurie Investment Fund, and Astellas Venture Management. As part of the closing of the financing, Lauren Silverman, Ph.D., Managing Director of the Novartis Option Fund and Ed Torres, Managing Director, Lilly Ventures, have joined Viamet’s board of directors.

San Jose, CA – SpineWorks Medical, Inc. announced today that it received CE-Mark authorization for commercialization of its SpineAlign™ Vertebral Body Replacement (VBR) System in the European Union and all countries recognizing the CE-Mark. The SpineAlign VBR is SpineWorks Medical’s first approved product that was designed for a transpedicular, minimally-invasive approach to vertebral body reconstruction and anterior spinal column support.

Drug Discovery and Development Company Focused on Metalloenzymes Closes Series A Round
Research Triangle Park , NC – Viamet Pharmaceuticals Inc., a biotechnology company targeting metalloenzymes in the fields of infectious disease, inflammation and oncology, announced today that it has closed a $4 million Series A financing round.